celecoxib has been researched along with Bone Cancer in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor." | 7.81 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. ( Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X, 2015) |
| "The goal of this study was to determine the effect of celecoxib, a selective COX-2 inhibitor, on the growth inhibition of osteosarcoma and its potential anticancer mechanisms." | 7.81 | Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line. ( Fan, GT; Ren, K; Shi, X; Wu, SJ; Zhao, JN; Zhou, X, 2015) |
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 7.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| " Celecoxib (CX) and minocycline hydrochloride (MH) have both been widely used in treating breast cancer; however, their combined effects on the osseous metastasis of breast cancer have not yet been studied." | 7.74 | The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| "Metastatic bone cancer pain is one of the most common clinical cancer pains and is caused by many factors." | 6.84 | Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. ( Liu, Z; Liu, ZL; Shen, XH; Tian, YZ; Xu, Y, 2017) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro." | 5.46 | The potential combinational effect of miR-34a with celecoxib in osteosarcoma. ( Chen, X; Huang, J; Liu, B; Peng, D; Shen, Y; Tao, H; Zhou, H, 2017) |
| "Chondrosarcomas are resistant to conventional chemo- and radiotherapy." | 5.36 | COX-2 expression in chondrosarcoma: a role for celecoxib treatment? ( Bovée, JV; Briaire-de Bruijn, I; Kalinski, T; Llombart-Bosch, A; Machado, I; Meijer, D; Schrage, YM; Taminiau, AH; van den Akker, BE, 2010) |
| " EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor." | 3.81 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. ( Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X, 2015) |
| "The goal of this study was to determine the effect of celecoxib, a selective COX-2 inhibitor, on the growth inhibition of osteosarcoma and its potential anticancer mechanisms." | 3.81 | Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line. ( Fan, GT; Ren, K; Shi, X; Wu, SJ; Zhao, JN; Zhou, X, 2015) |
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 3.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| " Celecoxib (CX) and minocycline hydrochloride (MH) have both been widely used in treating breast cancer; however, their combined effects on the osseous metastasis of breast cancer have not yet been studied." | 3.74 | The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| "When treatment was started prior to tumor cell implantation, doxycycline inhibited osteosarcoma tumor growth alone and in combination with celecoxib (30% and 33% reduction, respectively)." | 3.72 | Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. ( Cripe, TP; Dickens, DS, 2003) |
| "Metastatic bone cancer pain is one of the most common clinical cancer pains and is caused by many factors." | 2.84 | Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. ( Liu, Z; Liu, ZL; Shen, XH; Tian, YZ; Xu, Y, 2017) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro." | 1.46 | The potential combinational effect of miR-34a with celecoxib in osteosarcoma. ( Chen, X; Huang, J; Liu, B; Peng, D; Shen, Y; Tao, H; Zhou, H, 2017) |
| " Chronic administration of a cyclooxygenase (COX)-2 inhibitor is effective to bone cancer-related pain." | 1.37 | Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. ( Akira, S; DeClerck, YA; Hayashi, I; Hosono, K; Isono, M; Majima, M; Okamoto, H; Sakagami, H; Suzuki, T; Uematsu, S, 2011) |
| "The sites of secondary metastasis and the associated inflammatory microenvironment were evaluated." | 1.37 | Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. ( Ghosh, S; Gruber, HE; Mukherjee, P; Pathangey, LB; Roy, LD; Tinder, TL, 2011) |
| "Chondrosarcomas are resistant to conventional chemo- and radiotherapy." | 1.36 | COX-2 expression in chondrosarcoma: a role for celecoxib treatment? ( Bovée, JV; Briaire-de Bruijn, I; Kalinski, T; Llombart-Bosch, A; Machado, I; Meijer, D; Schrage, YM; Taminiau, AH; van den Akker, BE, 2010) |
| " There was significant difference between rats with EA combined with 5 mg/(kg." | 1.35 | [Analgesic effects of electroacupuncture combined with Celebrex on rats with tibial cancer pain]. ( Liu, Q; Mao-Ying, QL; Mi, WL; Ren, DH; Wang, YQ, 2008) |
| "Lung and bone metastasis and the associated inflammatory milieu were evaluated in the arthritic versus the non-arthritic mice." | 1.35 | Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. ( Das Roy, L; Gruber, HE; Mukherjee, P; Pathangey, LB; Schettini, JL; Tinder, TL, 2009) |
| "Osteosarcoma is the most common primary bone tumor, but the pathogenesis is not well understood." | 1.34 | Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. ( Choe, M; Choi, EM; Ha, KS; Han, JA; Kim, H; Kim, JI; Kim, SR; Kim, SS; Kim, YM; Lee, EJ; Park, JH, 2007) |
| "Treatment with Celecoxib reduced both microvessel density and tumor growth." | 1.33 | The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. ( Abdollahi, A; Ewerbeck, V; Gebhard, MM; Huber, PE; Klenke, FM; Sckell, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Kast, RE | 1 |
| Pramanik, R | 1 |
| Agarwala, S | 1 |
| Gupta, YK | 1 |
| Thulkar, S | 1 |
| Vishnubhatla, S | 1 |
| Batra, A | 1 |
| Dhawan, D | 1 |
| Bakhshi, S | 1 |
| Liu, Z | 1 |
| Xu, Y | 1 |
| Liu, ZL | 1 |
| Tian, YZ | 1 |
| Shen, XH | 1 |
| Chen, X | 1 |
| Peng, D | 1 |
| Shen, Y | 1 |
| Liu, B | 1 |
| Zhou, H | 1 |
| Tao, H | 1 |
| Huang, J | 1 |
| Garcia, M | 1 |
| Velez, R | 1 |
| Romagosa, C | 1 |
| Majem, B | 1 |
| Pedrola, N | 1 |
| Olivan, M | 1 |
| Rigau, M | 1 |
| Guiu, M | 1 |
| Gomis, RR | 1 |
| Morote, J | 1 |
| Reventós, J | 1 |
| Doll, A | 1 |
| Krzyzankova, M | 1 |
| Chovanova, S | 1 |
| Chlapek, P | 1 |
| Radsetoulal, M | 1 |
| Neradil, J | 1 |
| Zitterbart, K | 1 |
| Sterba, J | 1 |
| Veselska, R | 1 |
| Liu, G | 1 |
| Yu, MY | 1 |
| Huang, X | 1 |
| Zhu, D | 1 |
| Cheng, S | 1 |
| Ma, R | 1 |
| Gu, G | 1 |
| Liu, J | 1 |
| Wu, J | 1 |
| Zhou, L | 1 |
| Pan, C | 1 |
| Zhou, Y | 1 |
| Du, W | 1 |
| Chen, JM | 1 |
| Zhu, X | 1 |
| Shen, J | 1 |
| Chen, S | 1 |
| Liu, RY | 1 |
| Huang, W | 1 |
| Zhou, X | 1 |
| Shi, X | 1 |
| Ren, K | 1 |
| Fan, GT | 1 |
| Wu, SJ | 1 |
| Zhao, JN | 1 |
| Mao-Ying, QL | 1 |
| Ren, DH | 1 |
| Mi, WL | 1 |
| Liu, Q | 1 |
| Wang, YQ | 1 |
| Niu, G | 1 |
| Liao, Z | 1 |
| Cai, L | 1 |
| Wei, R | 1 |
| Sun, L | 1 |
| Das Roy, L | 1 |
| Pathangey, LB | 2 |
| Tinder, TL | 2 |
| Schettini, JL | 1 |
| Gruber, HE | 2 |
| Mukherjee, P | 2 |
| Schrage, YM | 1 |
| Machado, I | 1 |
| Meijer, D | 1 |
| Briaire-de Bruijn, I | 1 |
| van den Akker, BE | 1 |
| Taminiau, AH | 1 |
| Kalinski, T | 1 |
| Llombart-Bosch, A | 1 |
| Bovée, JV | 1 |
| Klenke, FM | 2 |
| Abdollahi, A | 2 |
| Bischof, M | 1 |
| Gebhard, MM | 2 |
| Ewerbeck, V | 2 |
| Huber, PE | 2 |
| Sckell, A | 2 |
| Isono, M | 1 |
| Suzuki, T | 1 |
| Hosono, K | 1 |
| Hayashi, I | 1 |
| Sakagami, H | 1 |
| Uematsu, S | 1 |
| Akira, S | 1 |
| DeClerck, YA | 1 |
| Okamoto, H | 1 |
| Majima, M | 1 |
| Roy, LD | 1 |
| Ghosh, S | 1 |
| Ellebaek, E | 1 |
| Engell-Noerregaard, L | 1 |
| Iversen, TZ | 1 |
| Froesig, TM | 1 |
| Munir, S | 1 |
| Hadrup, SR | 1 |
| Andersen, MH | 1 |
| Svane, IM | 1 |
| Barlow, M | 1 |
| Edelman, M | 1 |
| Glick, RD | 1 |
| Steinberg, BM | 1 |
| Soffer, SZ | 1 |
| Dickens, DS | 1 |
| Cripe, TP | 1 |
| Sonpavde, G | 1 |
| Hayes, TG | 1 |
| Tsai, YC | 1 |
| Wu, CT | 1 |
| Hong, RL | 1 |
| Lee, EJ | 1 |
| Choi, EM | 1 |
| Kim, SR | 1 |
| Park, JH | 1 |
| Kim, H | 1 |
| Ha, KS | 1 |
| Kim, YM | 1 |
| Kim, SS | 1 |
| Choe, M | 1 |
| Kim, JI | 1 |
| Han, JA | 1 |
| Carles, J | 1 |
| Font, A | 1 |
| Mellado, B | 1 |
| Domenech, M | 1 |
| Gallardo, E | 1 |
| González-Larriba, JL | 1 |
| Catalan, G | 1 |
| Alfaro, J | 1 |
| Gonzalez Del Alba, A | 1 |
| Nogué, M | 1 |
| Lianes, P | 1 |
| Tello, JM | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Medhurst, SJ | 1 |
| Walker, K | 1 |
| Bowes, M | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Muller, M | 1 |
| Hattenberger, M | 1 |
| Vaxelaire, J | 1 |
| O'Reilly, T | 1 |
| Wotherspoon, G | 1 |
| Winter, J | 1 |
| Green, J | 1 |
| Urban, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571] | Phase 3 | 108 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Malignant Melanoma. Phase I/II Study[NCT00197912] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Bone Cancer
| Article | Year |
|---|---|
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bone Neoplasms; Celecoxib; Humans; Osteo | 2023 |
5 trials available for celecoxib and Bone Cancer
| Article | Year |
|---|---|
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P | 2017 |
Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Cancer Pai | 2017 |
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C | 2012 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Dis | 2007 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
20 other studies available for celecoxib and Bone Cancer
| Article | Year |
|---|---|
The potential combinational effect of miR-34a with celecoxib in osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2017 |
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Topics: Animals; Bone Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progressi | 2014 |
LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Caffeic Acids; Celecoxib; Cell Differentiation; Cell Line, Tu | 2014 |
Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; bcl-2-Associated X Protein; Bone Neopla | 2014 |
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cell | 2015 |
Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line.
Topics: Apoptosis; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibit | 2015 |
[Analgesic effects of electroacupuncture combined with Celebrex on rats with tibial cancer pain].
Topics: Animals; Bone Neoplasms; Celecoxib; Combined Modality Therapy; Electroacupuncture; Male; Neoplasm Tr | 2008 |
The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice.
Topics: Alkaline Phosphatase; Animals; Apoptosis; Body Weight; Bone Neoplasms; Breast Neoplasms; Celecoxib; | 2008 |
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Autoimmune Dise | 2009 |
COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Celecoxib; Cell Survival; Chondrosarcoma; Cyclooxyge | 2010 |
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Di | 2011 |
Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice.
Topics: Animals; Behavior, Animal; Bone Neoplasms; Calcitonin Gene-Related Peptide; Carcinoma, Lewis Lung; C | 2011 |
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Neoplasms; Celecoxib; Collagen Type | 2011 |
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc | 2012 |
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cyclo | 2003 |
PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.
Topics: Adenocarcinoma; Bone Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Humans; Male; Middle Aged; Pro | 2005 |
Response of refractory osteosarcoma to thalidomide and celecoxib.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Celecoxib; Drug Resistance, Neoplasm | 2005 |
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
Topics: Animals; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; Lung Neoplasms; Mal | 2006 |
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.
Topics: Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cy | 2007 |
A rat model of bone cancer pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Body Tempera | 2002 |